Seagen Inc (SGEN)

[surf1944]

7:00AM Seattle Genetics highlights updated survival data from ADCETRIS pivotal trial in patients with relapsed or Refractory Hodgkin Lymphoma; median overall survival not reached after 26.5 month median follow-up (SGEN) 24.56 : Co announced updated survival data from a pivotal clinical trial of single-agent ADCETRIS in patients with relapsed or refractory Hodgkin lymphoma after autologous stem cell transplant showing that the median overall survival has not been reached after a 26.5 month median follow-up. Patients received 1.8 milligrams per kilogram of ADCETRIS every 3 weeks as a 30-minute outpatient intravenous infusion for up to 16 cycles. Patients received a median of nine cycles of ADCETRIS while on trial. The median age of patients in the pivotal trial was 31 years. Enrolled patients had received a median of 3.5 prior cancer-related systemic therapies, excluding ASCT. Seventy-one percent of patients had primary refractory disease, defined in the study protocol as patients who relapsed within three months of attaining CR or failed to achieve a CR, and 42 percent had not responded to their most recent prior therapy.